Federal judge denies Martin Shkreli all but one motion to dismiss monopoly claims in the FTC's Daraprim lawsuit

Nicole DeFeudis

Editor

“Pharma Bro” Martin Shkreli filed motions in May to dismiss the FTC’s claims that his company Vyera Pharmaceuticals boxed out competition and created a monopoly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Federal judge denies Martin Shkreli all but one motion to dismiss monopoly claims in the FTC's Daraprim lawsuit

Nicole DeFeudis

Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Fed­er­al judge de­nies Mar­tin Shkre­li all but one mo­tion to dis­miss mo­nop­oly claims in the FTC's Dara­prim law­suit

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Federal judge denies Martin Shkreli all but one motion to dismiss monopoly claims in the FTC's Daraprim lawsuit